What's Hot
View all perspectives
Dr. Antoni Chan
1 year ago
Auricular vagal nerve stimulation did not meaningfully improve RA disease activity. Further research of the novel intervention is required in RA, Baker MC, #ACR23 @RheumNow https://t.co/agLtRKdDTf
Leonard Calabrese LCalabreseDO
1 year ago
Kevin. Winthrop knocks it down on WHO is immunocompromised among rheumatic disease pts at Innovation Theater @CCalabreseDO #ACR23 @alhkim @AdamJBrownMD @ELittlejohnDO https://t.co/4hFtQgvaIf
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Abstr#2332 We need to compliment the Complement #SLE. Post-hoc analysis of SOC + PBO from Dapirolizumab Phase 2 RCT showed reduced response in patients who flared with low complement levels vs normal or persistent activity. To consider as a stratifier @RheumNow https://t.co/BcN6ExLD0s
Laura Cappelli
1 year ago
Come join us in 25 for the oral abstract session on #irAEs #ACR23 @jhrheumatology https://t.co/M3N9VCLNDb
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
TM66 at #ACR23
60 yo M w/ worsening PMR symptoms (polyarthralgias, difficulty raising arms) & b/l vision loss
PMH: PMR, central serous chorioretinopathy, HTN
VS: 100.2 F, HR 108
Labs:
- CRP 100 mg/dL, ESR 81 mm/h
- UA: proteinuria (100 mg/dL)
- ANA > 1:10,000, dsDNA > 300… https://t.co/T7Nov5vyoc https://t.co/3GuXVgh03Z
Dr. Antoni Chan
1 year ago
Treatment of lupus nephritis #ACR23
Dall’Era M, Furie R, Mosca M
@RheumNow https://t.co/Md2DsOrY5F
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
TM61 at #ACR23
23 yo M p/w ~3mo of sternal swelling
- US probable abscess, drained + multiple abx w/ no improvement
- XR R shoulder + L elbow nl but MRI abn
- MRI L elbow: possible osteomyelitis (OM)
- MRI R shoulder; clavicular osteolysis
- Bone Bx clavicle + L Ulna: Chronic… https://t.co/7s9PIwByTs https://t.co/wKaKfnncP5
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Late-Breaking Abstr#L10 Phase 2 crossover RCT of Dazodalibep, in #Sjogren pts with low ESSDAI but high ESSPRI. ESSPRI and FACIT-FATIGUE improved in both Stage 1 and also after X-over after 159 days. One to look out for those with high symptoms burden @RheumNow #ACRBest https://t.co/yGGrPmUOHU
Mithu Maheswaranathan, MD
1 year ago
🆕 2023 ACR Guidelines for Management of Interstitial Lung Disease (#ILD) in Systemic Autoimmune Rheumatic Diseases 🫁
🔸 Screening & Monitoring Recs
🔸 Treatment Guidelines ILD/RP-ILD
#RheumTwitter #PulmTwitter #MedTwitter #MedX https://t.co/JreVO0kgEf
Mithu Maheswaranathan, MD
1 year ago
👨⚖️ The Great Debate: should we use advanced therapies / biologics at disease onset in PMR & GCA? #ACR23
By Dr. Robert Spiera & Dr. Phil Seo @philseo #Vasculitis #PMR #GCA https://t.co/rkcUeEBLeZ
Mithu Maheswaranathan, MD
1 year ago
Clinical Year in Review at #ACR23
By @philseo (@jhrheumatology)
Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u
Paul Sufka, MD psufka
1 year ago
My takeaways from #ACR23 #ReviewCourse session on Inflammatory Eye Disease - Dr. Laura Kopplin:
1. Systemic therapy has better long term outcomes than topical treatments, but many/most ophthalmologists are uncomfortable with prescribing there.
2. FAST Trial: Methotrexate better… https://t.co/eoSeWVHsf0
Dr. John Cush RheumNow
1 year ago
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/TnCsgxOfCM https://t.co/HEd4NWnuuX
dX.Martínez
1 year ago
Lupus Nephritis and the Target with PR3+ in proliferative classes with more aggresive phenotype..
#Lupus biopsy.. #ACR23 https://t.co/fGJX57hWx4
Poster Hall